Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers – Regeneron
- Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers Regeneron
- US FDA expands use of Regeneron’s Libtayo as add-on treatment for skin cancer Reuters
- Regeneron, needing a turnaround, gains new use for cancer drug Yahoo Finance
- FDA Approves Cemiplimab as Adjuvant Immunotherapy for High-Risk CSCC Dermatology Times
- What Libtayo Means for High-Risk Cutaneous Squamous Cell Carcinoma Cure Today